SequelSEC

Cingulate Inc. CING

Pharmaceutical Preparations · CIK 0001862150 · Fiscal year ends 1231

Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$19.94M
Fiscal year ended 2025-12-31
Free cash flow
-$17.41M
Fiscal year ended 2025-12-31

Cingulate Inc. (CING) reported net income of -$22.45M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Cingulate Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Cingulate Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$19.94M-$15.64M-$22.76M-$17.50M-$20.68M-$7.08M
Net income-$22.45M-$16.56M-$23.53M-$17.68M-$20.71M-$7.18M
Research & development$9.77M$9.45M$15.49M$9.00M$8.41M$5.09M
Weighted-average diluted sharesshares 5.06Mshares 1.52MUnavailableUnavailableUnavailableUnavailable
Pretax income-$22.45M-$16.56M-$23.53M-$17.68M-$20.71M-$7.18M
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-4.44$-10.86$-311.99$-29.35UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$10.16M$6.20M$7.27M$8.51M$12.27M$1.99M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Cingulate Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$10.95M$12.21M$52.42K$5.36M$16.49M$1.20M
Total assets$15.07M$14.86M$3.49M$11.41M$22.89M$5.79M
Current assets$12.01M$12.66M$578.59K$7.87M$18.88M$1.79M
Total liabilities$12.56M$7.41M$10.36M$7.52M$2.04M$4.50M
Current liabilities$10.31M$4.97M$10.23M$7.01M$1.18M$3.36M
Total equity incl. NCI$2.51M$7.46M-$6.87M$3.88M$20.84M$1.29M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailable$14.62KUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.04M$1.27M$5.20M$762.36K$264.69K$975.11K

Cash flow

Cingulate Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$17.25M-$18.45M-$15.03M-$15.88M-$10.43M-$6.81M
Capital expenditures$162.14K$211.80K$224.10K$153.42K$814.74K$402.10K
Investing cash flow-$162.14K-$211.80K-$224.10K-$152.65K-$814.74K-$384.17K
Financing cash flow$16.15M$30.82M$9.95M$4.90M$26.54M$7.97M
Net change in cash-$1.26M$12.16M-$5.30M-$11.14M$15.30MUnavailable
Stock-based compensation$1.52M$995.48K$812.67K$800.80K$43.84KUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Cingulate Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$17.41M-$18.66M-$15.26M-$16.04M-$11.25M-$7.21M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio1.16x2.55x0.06x1.12x16.05x0.53x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CING in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-18View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-19View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.